Agomelatine
Use of Agomelatine
Agomelatine is a competitive antagonist of human and porcine serotonin (5-HT2C) receptors (pKi = 6.2 and 6.4, respectively) as well as human 5-HT2B receptors (pKi = 6.6). IC50 value: 6.2 (pKi, 5-HT2c); 6.6 (pKi, 5-HT2b)Target: 5-HT2C Receptor; 5-HT2B receptorIt is classified as a norepinephrine-dopamine disinhibitor (NDDI) due to its antagonism of the 5-HT2C receptor. Activation of 5-HT2C receptors by serotonin inhibits dopamine and norepinephrine release. Antagonism of 5-HT2C results in an enhancement of DA and NE release and activity of frontocortical dopaminergic and adrenergic pathways. Agomelatine is also a potent agonist at melatonin receptors which makes it the first melatonergic antidepressant. Agomelatine is an antidepressant drug.
Properties
Articles48
Spectrum
Product Description
| Common Name | Agomelatine |
| CAS Number | 138112-76-2 | Molecular Weight | 243.301 |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 478.8±28.0 °C at 760 mmHg |
| Molecular Formula | C15H17NO2 | Melting Point | 107-109ºC |
| MSDS | ChineseUSA | Flash Point | 243.4±24.0 °C |
| Symbol | 
GHS09 | Signal Word | Warning |
| Description | Agomelatine is a competitive antagonist of human and porcine serotonin (5-HT2C) receptors (pKi = 6.2 and 6.4, respectively) as well as human 5-HT2B receptors (pKi = 6.6). IC50 value: 6.2 (pKi, 5-HT2c); 6.6 (pKi, 5-HT2b)Target: 5-HT2C Receptor; 5-HT2B receptorIt is classified as a norepinephrine-dopamine disinhibitor (NDDI) due to its antagonism of the 5-HT2C receptor. Activation of 5-HT2C receptors by serotonin inhibits dopamine and norepinephrine release. Antagonism of 5-HT2C results in an enhancement of DA and NE release and activity of frontocortical dopaminergic and adrenergic pathways. Agomelatine is also a potent agonist at melatonin receptors which makes it the first melatonergic antidepressant. Agomelatine is an antidepressant drug. |
| Related Catalog | |
| References | [1]. Pan L, Kardono LB, Riswan S, Chai H, Carcache de Blanco EJ, Pannell CM, Soejarto DD, McCloud TG, Newman DJ, Kinghorn AD.Isolation and characterization of minor analogues of silvestrol and other constituents from a large-scale re-collection of Aglaia foveolata.J Nat Prod. 2010 Nov 29;73(11):1873-8. [2]. Zajecka J, Schatzberg A, Stahl S. et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010 Apr;30(2):135-44. [3]. Randy A Sansone, Lori A Sansone. Agomelatine A Novel Antidepressant. Innov Clin Neurosci. 2011 November; 8(11): 10-14. [4]. Michele Fornaro, Davide Prestia, Salvatore Colicchio, and Giulio Perugi. A Systematic, Updated Review on the Antidepressant Agomelatine Focusing on its Melatonergic Modulation. Curr Neuropharmacol. 2010 September; 8(3): 287-304. [5]. Agomelatine |
| Density | 1.1±0.1 g/cm3 |
| Boiling Point | 478.8±28.0 °C at 760 mmHg |
| Melting Point | 107-109ºC |
| Molecular Formula | C15H17NO2 |
| Molecular Weight | 243.301 |
| Flash Point | 243.4±24.0 °C |
| Exact Mass | 243.125931 |
| PSA | 38.33000 |
| LogP | 2.27 |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
| Index of Refraction | 1.582 |
| Storage condition | -20°C Freezer |
English
